Two candidate vaccines to prevent infection with human papillomavirus (HPV) Types 11 and
16 were studied in similar double-blind, placebo-controlled, dose-escalation trials. L1 virus …

A post hoc analysis was performed using combined data from two Phase I tolerability/
immunogenicity studies of monovalent human papillomavirus type 11 (HPV11) or HPV16 L1 …

We conducted an extended follow-up study (March 2006–May 2008) to assess the longer
term efficacy of a prophylactic monovalent human papillomavirus (HPV) type 16 L1 virus-like …

OBJECTIVE To evaluate the immunogenicity, reactogenicity, and tolerability of a prototype
human papillomavirus (HPV) 16 viruslike particle (VLP) vaccine directed against the L1 …

In this study, we evaluated the potency of a human papillomavirus (HPV) virus-like particle
(VLP)-based vaccine at generating HPV type 11 (HPV-11)-specific cellular and humoral …

Background: Studies in animal models have shown that systemic immunization with a
papillomavirus virus-like particle (VLP) vaccine composed of L1, a major structural viral …

Human papillomavirus (HPV) infection causes cervical cancer and genital warts. Young
women (1106) were randomized to receive one of three formulations of a quadrivalent HPV …

Viruslike particles (VLPs) produced from the L1 protein of several papillomaviruses have
induced protection from infection after live challenge in animal models. In the present study …

Background Vaccination against the most common oncogenic human papillomavirus (HPV)
types, HPV-16 and HPV-18, could prevent development of up to 70% of cervical cancers …

Candidate prophylactic vaccines based on papillomavirus L1 virus-like particles (VLPs) are
currently in human clinical trials. The main long-term goal of the vaccine is to reduce the …